These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12208144)

  • 1. In randomized controlled trials, should subjects in both placebo and drug groups be expected to guess that they are taking drug 50% of the time?
    Desbiens NA
    Med Hypotheses; 2002 Sep; 59(3):227-32. PubMed ID: 12208144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of treatment allocation in a randomised, double-blinded, placebo-controlled trial.
    Popovic M; Cesana-Nigro N; Winzeler B; Thomann R; Schütz P; Müller B; Christ-Crain M; Blum CA
    Swiss Med Wkly; 2019 Jul; 149():w20114. PubMed ID: 31340056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactions to treatment debriefing among the participants of a placebo controlled trial.
    Di Blasi Z; Crawford F; Bradley C; Kleijnen J
    BMC Health Serv Res; 2005 Apr; 5(1):30. PubMed ID: 15847683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Some reflexions about double blind].
    Boussageon R; Gueyffier F; Moreau A; Gansel Y; Boussageon V
    Encephale; 2008 Sep; 34(4):347-51. PubMed ID: 18922236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placebo--efficacy and adverse effects in controlled clinical trials.
    Weihrauch TR; Gauler TC
    Arzneimittelforschung; 1999 May; 49(5):385-93. PubMed ID: 10367099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double blind: double talk or are there ways to do better research.
    Ney PG; Collins C; Spensor C
    Med Hypotheses; 1986 Oct; 21(2):119-26. PubMed ID: 3641026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The placebo response in clinical trials-the current state of play.
    Enck P; Klosterhalfen S
    Complement Ther Med; 2013 Apr; 21(2):98-101. PubMed ID: 23497810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Placebos, drug effects, and study design: a clinician's guide.
    Quitkin FM
    Am J Psychiatry; 1999 Jun; 156(6):829-36. PubMed ID: 10360119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considering the case for an antidepressant drug trial involving temporary deception: a qualitative enquiry of potential participants.
    Dowrick CF; Hughes JG; Hiscock JJ; Wigglesworth M; Walley TJ
    BMC Health Serv Res; 2007 Apr; 7():64. PubMed ID: 17470280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blinding strategies in the conduct and reporting of a randomized placebo-controlled device trial.
    Houweling AH; Shapiro S; Cohen JM; Kahn SR
    Clin Trials; 2014 Oct; 11(5):547-52. PubMed ID: 24902921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active placebo control groups of pharmacological interventions were rarely used but merited serious consideration: a methodological overview.
    Jensen JS; Bielefeldt AØ; Hróbjartsson A
    J Clin Epidemiol; 2017 Jul; 87():35-46. PubMed ID: 28342907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
    Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
    Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can the blind see? Participant guess about treatment arm assignment may influence outcome in a clinical trial of bupropion for smoking cessation.
    Schnoll RA; Epstein L; Audrain J; Niaura R; Hawk L; Shields PG; Lerman C; Wileyto EP
    J Subst Abuse Treat; 2008 Mar; 34(2):234-41. PubMed ID: 17600649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why use placebos in clinical trials? A narrative review of the methodological literature.
    Vickers AJ; de Craen AJ
    J Clin Epidemiol; 2000 Feb; 53(2):157-61. PubMed ID: 10729687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials.
    Carpenter DJ; Fong R; Kraus JE; Davies JT; Moore C; Thase ME
    J Clin Psychiatry; 2011 Nov; 72(11):1503-14. PubMed ID: 21367354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Participant expectancies in double-blind randomized placebo-controlled trials: potential limitations to trial validity.
    Colagiuri B
    Clin Trials; 2010 Jun; 7(3):246-55. PubMed ID: 20421243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Types, frequencies, and burden of nonspecific adverse events of drugs: analysis of randomized placebo-controlled clinical trials.
    Mahr A; Golmard C; Pham E; Iordache L; Deville L; Faure P
    Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):731-741. PubMed ID: 28176407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The placebo is powerful: estimating placebo effects in medicine and psychotherapy from randomized clinical trials.
    Wampold BE; Minami T; Tierney SC; Baskin TW; Bhati KS
    J Clin Psychol; 2005 Jul; 61(7):835-54. PubMed ID: 15827993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.